ScoreWhy is Henan Taloph Pharmaceutical Stock Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 2.63%
- The company has been able to generate a Return on Capital Employed (avg) of 2.63% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 5.18% and Operating profit at -3.09% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 1.46% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 5.18% and Operating profit at -3.09% over the last 5 years
4
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(9M) At CNY 1,186.9 MM has Grown at -11.29%
- INTEREST COVERAGE RATIO(Q) Lowest at 154.13
- INVENTORY TURNOVER RATIO(HY) Lowest at 2.77 times
5
With ROE of 2.58%, it has a very expensive valuation with a 2.27 Price to Book Value
- Over the past year, while the stock has generated a return of 28.12%, its profits have fallen by -63.5%
- At the current price, the company has a high dividend yield of 0.2
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Henan Taloph Pharmaceutical Stock Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Henan Taloph Pharmaceutical Stock Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Henan Taloph Pharmaceutical Stock Co., Ltd.
43.91%
1.38
39.07%
China Shanghai Composite
24.7%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
5.18%
EBIT Growth (5y)
-3.09%
EBIT to Interest (avg)
1.01
Debt to EBITDA (avg)
6.01
Net Debt to Equity (avg)
0.49
Sales to Capital Employed (avg)
0.79
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
30.84%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.63%
ROE (avg)
1.46%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
88
Industry P/E
Price to Book Value
2.27
EV to EBIT
63.52
EV to EBITDA
31.95
EV to Capital Employed
1.77
EV to Sales
2.65
PEG Ratio
NA
Dividend Yield
0.16%
ROCE (Latest)
2.79%
ROE (Latest)
2.58%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
PRE-TAX PROFIT(Q)
At CNY 9.6 MM has Grown at 460.25%
NET PROFIT(Q)
At CNY 5.97 MM has Grown at 278.88%
RAW MATERIAL COST(Y)
Fallen by -15.15% (YoY
-11What is not working for the Company
NET SALES(9M)
At CNY 1,186.9 MM has Grown at -11.29%
INTEREST COVERAGE RATIO(Q)
Lowest at 154.13
INVENTORY TURNOVER RATIO(HY)
Lowest at 2.77 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 1.51 times
INTEREST(Q)
Highest at CNY 16.61 MM
OPERATING PROFIT(Q)
Lowest at CNY 25.6 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 6.03 %
Here's what is working for Henan Taloph Pharmaceutical Stock Co., Ltd.
Pre-Tax Profit
At CNY 9.6 MM has Grown at 460.25%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 5.97 MM has Grown at 278.88%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Raw Material Cost
Fallen by -15.15% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Henan Taloph Pharmaceutical Stock Co., Ltd.
Interest
At CNY 16.61 MM has Grown at 59.71%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Interest Coverage Ratio
Lowest at 154.13
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Net Sales
At CNY 1,186.9 MM has Grown at -11.29%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Interest
Highest at CNY 16.61 MM
in the last five periods and Increased by 59.71% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Operating Profit
Lowest at CNY 25.6 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at 6.03 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Inventory Turnover Ratio
Lowest at 2.77 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 1.51 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
